Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?Zacks Investment Research • 02/18/25
International Markets and Exelixis (EXEL): A Deep Dive for InvestorsZacks Investment Research • 02/17/25
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025Business Wire • 02/15/25
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in FocusZacks Investment Research • 02/12/25
Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/12/25
Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate UpdateBusiness Wire • 02/11/25
Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key MetricsZacks Investment Research • 02/06/25
Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025Business Wire • 01/28/25
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025Business Wire • 01/25/25
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025Business Wire • 01/24/25
4 PEG-Based Value Stocks to Neutralize Trump 2.0-Led Market VolatilityZacks Investment Research • 01/21/25